Optimization of SARS-CoV-2 Spike Protein Expression in the Silkworm and Induction of Efficient Protective Immunity by Inoculation With Alum Adjuvants.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 28 10 2021
accepted: 20 12 2021
entrez: 31 1 2022
pubmed: 1 2 2022
medline: 10 2 2022
Statut: epublish

Résumé

The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing a spread of coronavirus disease 2019 (COVID-19) globally. In order to end the COVID-19 pandemic, an effective vaccine against SARS-CoV-2 must be produced at low cost and disseminated worldwide. The spike (S) protein of coronaviruses plays a pivotal role in the infection to host cells. Therefore, targeting the S protein is one of the most rational approaches in developing vaccines and therapeutic agents. In this study, we optimized the expression of secreted trimerized S protein of SARS-CoV-2 using a silkworm-baculovirus expression vector system and evaluated its immunogenicity in mice. The results showed that the S protein forming the trimeric structure was the most stable when the chicken cartilage matrix protein was used as the trimeric motif and could be purified in large amounts from the serum of silkworm larvae. The purified S protein efficiently induced antigen-specific antibodies in mouse serum without adjuvant, but its ability to induce neutralizing antibodies was low. After examining several adjuvants, the use of Alum adjuvant was the most effective in inducing strong neutralizing antibody induction. We also examined the adjuvant effect of paramylon from

Identifiants

pubmed: 35095889
doi: 10.3389/fimmu.2021.803647
pmc: PMC8789674
doi:

Substances chimiques

Adjuvants, Immunologic 0
Alum Compounds 0
Antibodies, Neutralizing 0
Antibodies, Viral 0
COVID-19 Vaccines 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0
aluminum sulfate 34S289N54E
Aluminum Hydroxide 5QB0T2IUN0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

803647

Informations de copyright

Copyright © 2022 Masuda, Lee, Miyata, Mon, Sato, Oyama, Sakurai, Yasuda, Takahashi, Ueda, Kato, Nishida, Karasaki, Kakino, Ebihara, Nagasato, Hino, Nakashima, Suzuki, Tonooka, Tanaka, Moriyama, Nakatake, Fujita and Kusakabe.

Déclaration de conflit d'intérêts

AN and KSu are employed by euglena Co., Ltd. HN is employed by KAICO Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
PLoS Pathog. 2018 Apr 23;14(4):e1007009
pubmed: 29684066
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
Immunity. 2010 Oct 29;33(4):492-503
pubmed: 21029960
Science. 2020 Jul 17;369(6501):330-333
pubmed: 32366695
Lancet Infect Dis. 2021 Oct;21(10):1383-1394
pubmed: 33887208
Front Immunol. 2020 Nov 06;11:589833
pubmed: 33240278
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Appl Microbiol Biotechnol. 2010 Jan;85(3):459-70
pubmed: 19830419
Nat Rev Drug Discov. 2021 Jun;20(6):454-475
pubmed: 33824489
J Virol. 2019 Nov 13;93(23):
pubmed: 31534041
AMB Express. 2020 Aug 17;10(1):147
pubmed: 32804287
Emerg Microbes Infect. 2020 Dec;9(1):2076-2090
pubmed: 32897177
Nat Commun. 2021 Mar 3;12(1):1403
pubmed: 33658497
AIDS Res Hum Retroviruses. 2008 Feb;24(2):301-14
pubmed: 18284327
Food Sci Nutr. 2016 May 20;5(2):205-214
pubmed: 28265355
J Virol. 2000 Jun;74(12):5716-25
pubmed: 10823881
Mol Cell. 2020 May 21;78(4):779-784.e5
pubmed: 32362314
J Biol Chem. 2015 Mar 20;290(12):7436-42
pubmed: 25635058
J Infect. 2020 Aug;81(2):e16-e25
pubmed: 32335169
Biochem Biophys Res Commun. 2020 Aug 20;529(2):257-262
pubmed: 32703420
J Hematol Oncol. 2009 Jun 10;2:25
pubmed: 19515245
Science. 2020 Aug 7;369(6504):650-655
pubmed: 32571838
J Biol Chem. 1995 Sep 29;270(39):23150-4
pubmed: 7559460
Nature. 2020 Aug;584(7821):450-456
pubmed: 32698192
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
J Gen Virol. 2018 Jul;99(7):917-926
pubmed: 29851377
J Virol. 2011 Dec;85(23):12201-15
pubmed: 21937658
Nat Immunol. 2015 Apr;16(4):343-53
pubmed: 25789684
Nature. 2020 Oct;586(7830):572-577
pubmed: 32726802
Nature. 2021 Jun;594(7862):253-258
pubmed: 33873199
Cell. 2021 Apr 15;184(8):2183-2200.e22
pubmed: 33756110
Vet Res. 2021 Jul 7;52(1):102
pubmed: 34233749
Adv Mater. 2020 Oct;32(40):e2004210
pubmed: 32864794
PLoS Pathog. 2014 Nov 06;10(11):e1004502
pubmed: 25375324
Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7001-7003
pubmed: 32165541
NPJ Vaccines. 2021 May 21;6(1):78
pubmed: 34021167
Science. 2020 Sep 18;369(6510):1501-1505
pubmed: 32703906
Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5871-6
pubmed: 19321428
EBioMedicine. 2021 Jan;63:103197
pubmed: 33422991
Nat Commun. 2021 Mar 1;12(1):1346
pubmed: 33649323
Nature. 2020 Oct;586(7830):589-593
pubmed: 32785213
Lancet. 2021 Feb 20;397(10275):682-694
pubmed: 33524311
Appl Biochem Biotechnol. 2014 Apr;172(8):3978-88
pubmed: 24599668
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Nat Microbiol. 2020 Apr;5(4):562-569
pubmed: 32094589
PLoS One. 2008;3(11):e3647
pubmed: 18985154
Sci Rep. 2020 Nov 18;10(1):20085
pubmed: 33208827
Nat Struct Biol. 1998 Aug;5(8):687-91
pubmed: 9699631
Nat Struct Mol Biol. 2016 Oct;23(10):899-905
pubmed: 27617430
Mol Cell Proteomics. 2021;20:100058
pubmed: 33077685
PLoS One. 2012;7(4):e35421
pubmed: 22536382
J Virol. 2002 May;76(9):4634-42
pubmed: 11932429
ACS Infect Dis. 2021 Aug 13;7(8):2546-2564
pubmed: 34260218
Lancet. 2021 Dec 19;396(10267):1979-1993
pubmed: 33220855
Infect Immun. 2011 Oct;79(10):4260-75
pubmed: 21807905
Adv Sci (Weinh). 2021 Aug;8(16):e2100985
pubmed: 34176237
Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15214-9
pubmed: 25288733
Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12262-12267
pubmed: 27791014
Protein Expr Purif. 2020 Oct;174:105686
pubmed: 32504802
Mol Biotechnol. 2015 Aug;57(8):735-45
pubmed: 25832992
Vaccine. 2015 Jan 1;33(1):117-25
pubmed: 25448101
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
Pharmaceutics. 2021 Mar 27;13(4):
pubmed: 33801614

Auteurs

Akitsu Masuda (A)

Laboratory of Insect Genome Science, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan.

Jae Man Lee (JM)

Laboratory of Creative Science for Insect Industries, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan.

Takeshi Miyata (T)

Department of Biochemistry and Biotechnology, Faculty of Agriculture, Kagoshima University, Kagoshima, Japan.

Hiroaki Mon (H)

Laboratory of Insect Genome Science, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan.

Keita Sato (K)

Department of Biochemistry and Biotechnology, Faculty of Agriculture, Kagoshima University, Kagoshima, Japan.

Kosuke Oyama (K)

Laboratory of Protein Structure, Function and Design, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.

Yasuteru Sakurai (Y)

Department of Emerging Infectious Diseases, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan.
National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University, Nagasaki, Japan.

Jiro Yasuda (J)

Department of Emerging Infectious Diseases, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan.
National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University, Nagasaki, Japan.

Daisuke Takahashi (D)

Laboratory of Protein Structure, Function and Design, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.

Tadashi Ueda (T)

Laboratory of Protein Structure, Function and Design, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.

Yuri Kato (Y)

Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.

Motohiro Nishida (M)

Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.

Noriko Karasaki (N)

Laboratory of Insect Genome Science, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan.

Kohei Kakino (K)

Laboratory of Insect Genome Science, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan.

Takeru Ebihara (T)

Laboratory of Insect Genome Science, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan.

Takumi Nagasato (T)

Laboratory of Insect Genome Science, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan.

Masato Hino (M)

Laboratory of Sanitary Entomology, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan.

Ayaka Nakashima (A)

The Research and Development Department, Euglena Co., Ltd, Tokyo, Japan.

Kengo Suzuki (K)

The Research and Development Department, Euglena Co., Ltd, Tokyo, Japan.

Yoshino Tonooka (Y)

Laboratory of Insect Genome Science, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan.

Miyu Tanaka (M)

Laboratory of Insect Genome Science, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan.

Takato Moriyama (T)

Laboratory of Insect Genome Science, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan.

Hirokazu Nakatake (H)

The Production Department, KAICO Ltd, Fukuoka, Japan.

Ryosuke Fujita (R)

Laboratory of Sanitary Entomology, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan.

Takahiro Kusakabe (T)

Laboratory of Insect Genome Science, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH